Skip to
  1. Homepage
  2. Rare diseases
  3. Search
Simple search

Simple search

(*) mandatory field


Other search option(s)

Aicardi-Goutières syndrome

Synonym(s) Encephalopathy with basal ganglia calcification
Encephalopathy with intracranial calcification and chronic lymphocytosis of cerebrospinal fluid
Prevalence Unknown
Inheritance Autosomal dominant
or Autosomal recessive
Age of onset Infancy
  • G31.8
  • C0393591
  • C535607
MedDRA -


Disease definition

Aicardi-Goutières syndrome (AGS) is an inherited, subacute encephalopathy characterised by the association of basal ganglia calcification, leukodystrophy and cerebrospinal fluid (CSF) lymphocytosis.


Just over 120 cases have been reported in the literature so far.

Clinical description

The majority of affected infants are born at full term with normal growth parameters. Onset occurs within the first few days or month of life with severe, subacute encephalopathy (feeding problems, irritability and psychomotor regression or delay) associated with epilepsy (53% of cases), chilblain skin lesions on the extremities (43% of cases) and episodes of aseptic febrile illness (40% of cases). Symptoms progress over several months (with the development of microcephaly and pyramidal signs) before the disease course stabilises. However, less severe forms have been described with onset after 1 year of age and preservation of language skills and cognitive function, and normal head circumference. The phenotype shows inter- and intrafamilial variation.


In 2006, causative mutations were identified in four genes: TREX1, encoding a 3'->5' exonuclease, and in RNASEH2A, RNASEH2B and RNASEH2C, genes encoding subunits of the RNase H2 endonuclease complex. TREX1 (25% of cases), RNASEH2C (14% of cases) and RNASEH2A (4% of cases) mutations result in a severe phenotype, whereas RNASEH2B (41% of cases) mutations generally lead to a milder phenotype. No mutations in any of these genes are found in the remaining cases.

Diagnostic methods

Calcification (involving the basal ganglia and white matter), cystic leukodystrophy (predominantly frontotemporal) and cortical-subcortical atrophy are the cardinal features for diagnosis, often associated with atrophy of the corpus callosum, brain stem and cerebellum. Elevated IFN-alpha levels and CSF lymphocytosis are very frequent but not constant findings (90% and 75% of cases, respectively) in the initial stage of the disease but tend to normalise or resolve within a few years. The diagnosis is confirmed by detection of a mutation in one of the four disease-causing genes.

Differential diagnosis

The principle differential diagnoses are TORCH congenital infections (toxoplasma, rubella, CMV, HSV1 and HSV2).

Antenatal diagnosis

Prenatal diagnosis is feasible through molecular analysis of amniotic fluid or trophoblasts.

Genetic counseling

Transmission is autosomal recessive but rare cases of autosomal dominant inheritance have been reported.

Management and treatment

Treatment is symptomatic (management of the feeding problems, psychomotor delay and, if present, epilepsy).


Around 80% of patients presenting with the severe form die within the first 10 years of life but prolonged survival after the first decade of life has been reported in milder forms.

Expert reviewer(s)

  • Dr Pierre BLANC
  • Pr Isabelle CREVEAUX

(*) Required fields.

Attention: Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.

Captcha image

Detailed information

Review article
Clinical genetics review
Get Acrobat Reader
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.